about
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancerPhase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiformeThe Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control StudyACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised coPhase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies.Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.Haematological recovery following high-dose cyclophosphamide with autologous bone marrow transplantation.Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.Answering patients' needs: oral alternatives to intravenous therapy.Capecitabine as adjuvant treatment for stage III colon cancer.Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery.Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.Treatment for anthracycline-pretreated metastatic breast cancer.Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxaneChromosome instability and benefit from adjuvant anthracyclines in breast cancer.Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trialPharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialSubgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast CancerSafety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy.A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.'Tablet burden' in patients with metastatic breast cancer.Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
P50
Q24596171-e5e37a94-4251-6289-c276-6bb135f2dc0bQ26768140-7FF841E9-EE75-4214-8DEE-C5F7B6F24611Q28205919-72097E88-F2B6-4A14-8B8F-ED54A938E5C5Q28552519-4CA5F687-65D5-4AF0-A2AA-19FBD4179B73Q30301332-30F9DA6F-E9AC-4B8C-AE0A-5CF68D116727Q30316930-1AD31CA1-EEF6-4B26-8A39-EC31B0531B86Q33193532-ECCE3672-25E3-4E52-84A9-2C55968403F6Q33342218-07F031FD-5BBF-497B-B3B7-B8A62ADD4C84Q33348708-C0B8E428-6887-43CA-8D5F-CB792A8DDAC5Q33363752-4A29C783-6E2F-41AB-8621-E39EDB360E55Q33365345-6F8C2B7F-3313-4392-B41C-5AA7DD8CF554Q33419663-D73C9D00-B6FA-4730-9B15-A68F6E76378BQ33849656-677F34E5-AB43-4C7A-BF8D-7885278FB2A1Q33978749-51ABBB26-3646-49B6-936D-410D73C54F35Q34390887-DC879031-D6B8-48F9-9820-34747113DDCCQ34429990-4650F771-EAC7-4EFA-8CDE-45FE7DC5BA28Q34519158-9F7FA423-E0D9-4657-85E1-819DD77B1E1FQ34524041-559775C1-4776-4E0E-9DFA-8ECA99142EBAQ34605702-DC864079-2EAB-41AE-BC1A-7B1A03872106Q34632080-313E9BDE-3B08-47BC-B16B-077D9B293AABQ34974760-DE716243-E000-4870-94C1-C19D3B073848Q35009959-F8370875-DD07-4919-8F84-3B18E8182463Q35511840-47A0F44C-5DB4-4E6E-AF0A-CB8949E9D966Q35721526-6F46BB68-FC5E-41DE-9948-23D42A37039DQ36075278-83375340-C1A6-4EA7-96A5-E22FDE5E4B20Q36322815-C6188183-5BCF-45ED-8825-C42A7AD4637FQ36614123-EBD81E1D-7983-4088-AD38-5512A5EC431CQ37052387-1A47206D-CE87-42DC-B127-18F12D8590F1Q37079932-AC7321C5-D663-42C0-9A47-7E16F4C38E92Q37206289-DDA1D6B8-3825-42CB-9809-27BBFB3212C6Q37362627-6A292DBA-DD28-4C6A-B82A-B8E45AB1907BQ37777290-6E8EB244-2068-4230-94A1-010303B9A611Q38376300-0E75147A-3452-4139-A4E1-1BC86C7DE62DQ40572510-AC0C6A69-D3DA-4CFC-96C4-BCD7264F91BAQ40580831-A0CB95F3-C439-4A4C-B9FA-C3BB2B54DF26Q40997598-4E52EA7B-2EF9-402F-A87A-75B7B30EC675Q42653377-66F9A8A6-9F5E-42C4-B9FF-923BD4479C25Q43178034-C5F9212D-091A-4D82-B055-F81564C2AF39Q44663943-41B4CBED-0999-4F1C-A467-EFCB6FD7DF2AQ44817903-E57B22AF-848A-42E5-A3A3-7672CE7DEC37
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
ricercatore
@it
հետազոտող
@hy
name
Chris Twelves
@ast
Chris Twelves
@br
Chris Twelves
@ca
Chris Twelves
@cs
Chris Twelves
@cy
Chris Twelves
@da
Chris Twelves
@de
Chris Twelves
@de-at
Chris Twelves
@de-ch
Chris Twelves
@en
type
label
Chris Twelves
@ast
Chris Twelves
@br
Chris Twelves
@ca
Chris Twelves
@cs
Chris Twelves
@cy
Chris Twelves
@da
Chris Twelves
@de
Chris Twelves
@de-at
Chris Twelves
@de-ch
Chris Twelves
@en
altLabel
Christopher J Twelves
@br
Christopher J Twelves
@ca
Christopher J Twelves
@cs
Christopher J Twelves
@cy
Christopher J Twelves
@da
Christopher J Twelves
@de
Christopher J Twelves
@de-at
Christopher J Twelves
@de-ch
Christopher J Twelves
@en
Christopher J Twelves
@en-ca
prefLabel
Chris Twelves
@ast
Chris Twelves
@br
Chris Twelves
@ca
Chris Twelves
@cs
Chris Twelves
@cy
Chris Twelves
@da
Chris Twelves
@de
Chris Twelves
@de-at
Chris Twelves
@de-ch
Chris Twelves
@en
P214
P244
P950
P106
P1153
7006370007
P2031
1986-01-01T00:00:00Z
P2038
Chris_Twelves
P21
P213
0000 0000 3625 7191
P214
P244
n2006181734
P31
P6634
chris-twelves-89950669
P735
P7859
lccn-n2006181734